The DUS1L Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for targeted disruption of the DUS1L gene in the HT29 human colorectal adenocarcinoma cell line. This polyclonal population provides a heterogeneous loss-of-function model, suitable for studying the functional consequences of DUS1L disruption without the constraints of single-cell clonal selection. The product enables researchers to interrogate the role of DUS1L-dependent tRNA modification in cancer cell biology, leveraging the well-characterized HT29 background.
HT29 cells are a widely utilized human colon adenocarcinoma cell line derived from a female patient, exhibiting epithelial morphology. These cells serve as a classic in vitro model for intestinal epithelial barrier function, drug absorption studies, and colorectal cancer research. Their robust growth and well-documented signaling networks make them particularly valuable for investigating oncogenic processes and the impact of genetic perturbations on tumor cell behavior.
DUS1L encodes a dihydrouridine synthase that catalyzes the reduction of uridine to dihydrouridine at specific positions in tRNA molecules, a modification critical for tRNA stability and translational fidelity. DUS1L functions within the tRNA modification pathway and RNA metabolism, interacting with other tRNA modification enzymes and potentially associating with the ribosomal machinery. Its activity is regulated by cell cycle and metabolic signals, though specific upstream regulators remain poorly defined. Downstream consequences of DUS1L action include modulation of tRNA structure and the efficiency of protein synthesis. Members of the DUS enzyme family, tRNA substrates, and the dihydrouridine modification complex represent key components of this network. Disruption of DUS1L is anticipated to diminish dihydrouridine levels, thereby altering tRNA conformation and translation dynamics.
In the context of HT29 colorectal cancer cells, DUS1L knockout is predicted to abolish dihydrouridine synthesis, leading to altered tRNA stability and potentially impaired translational fidelity. Such modifications may affect cell proliferation rates, stress responses, and oncogenic signaling pathways. Given the high translational demand of cancer cells, loss of DUS1L function could reveal synthetic vulnerabilities or adaptive mechanisms in colorectal tumors. This model thus provides a physiologically relevant system to dissect the contribution of tRNA modification to colorectal cancer biology, particularly in relation to translational dysregulation and tumor maintenance.
The DUS1L Knockout HT29 Polyclonal Cells are suited for a broad range of experimental applications, including analysis of tRNA modification status via mass spectrometry, assessment of protein synthesis changes by Western blotting and RNA-seq, and evaluation of cell growth through proliferation and colony formation assays. Researchers can combine these cells with wild-type HT29 controls to conduct comparative studies on translational control mechanisms, RNA metabolism, and cancer cell fitness. This product is especially valuable for high-content screens, mechanistic investigations of epitranscriptomic regulation, and the development of novel therapeutic strategies targeting translational pathways in colorectal cancer. For additional details or ordering information, please contact Ascent Research.
